Metalloproteinases (MMPs) and their natural inhibitors (TIMPs) contribute to the regulation of tumor microenvironment. Their expressions are deregulated in almost all human cancers. We report a novel approach to gene therapy of hepatocellular carcinoma (HCC), using repeated injections of DNA plasmids encoding the tissue inhibitors of metalloproteinases (TIMPs) TIMP-2 or TIMP-3, and a novel competent formulation of gene transfer based on nontoxic cationic cholesterol derivatives. The new gene delivery system was efficient in demonstrating the antitumor efficiency of TIMP-2 or TIMP-3 in inhibiting tumor growth of human HuH7 HCC cells xenografted into nude mice. We show, for the first time, an in vivo effect of TIMP-3 in delaying HCC tumor growth. No treatment-related toxicity was noted. An inhibition of angiogenesis and tumor necrosis accompanied the inhibitory effects of TIMP-2 or TIMP-3 on tumor expansion and invasion. We also report a bystander effect produced by transfected HuH7 tumor cells mixed with untransfected cells in 1:1 ratio in culture that resulted in killing 98% of cells within 96 h. In addition, the soluble forms of TIMP-2 and TIMP-3 expressed by transfected cells exerted a cytotoxic effect on untransfected HuH7 cell cultures. Taken together, these results demonstrate the potential efficacy of repeated treatment of secreted TIMP-2 and TIMP-3 for the design of nonviral gene therapy for hepatocarcinoma.
H epatocellular carcinoma (HCC) is one of the three leading causes of cancer deaths. The major risk factors include hepatitis B and C viral infection, exposure to aflatoxin, and alcoholic liver disease. Epidemiological studies of HCC indicate an increase in mortality from primary liver cancer and suggest that this might be related to the HCV epidemic.
1,2 Surgical resection is curative but restricted to patients with unaltered liver function. 3 Other therapies include percutaneous intratumoral ethanol injection, 4 transarterial chemoembolization, 5 and radiofrequency thermal ablation, 6 but recurrences are common. Chemotherapy and hormone therapies have shown no survival benefit. HCC is clearly a disease for which alternative therapeutic strategies must be developed. HCC is largely restricted to the liver. Thus, local/regional gene therapy represents an attractive treatment modality. Gene transfer can be delivered by either direct injection into HCC tumors, or via the hepatic artery, from which HCCs derive the majority of their blood supplies. [7] [8] [9] Our previous reports demonstrated that therapeutic strategies, using injections of adenovirus vectors encoding either the herpes simplex virus thymidine kinase (HSVtk), or p53, displayed efficient antitumor activity, and inhibited the growth of rat HCC chemically induced by diethylnitrosamine. [10] [11] [12] We present herein a novel therapeutic strategy, which involves gene transfer of plasmids encoding selective inhibitors of specific matrix metalloproteinases (MMPs) for treatment of HCC, using a novel class of nonviral vectors. The MMPs are a family of 24 secreted and membrane-associated neutral endopeptidases that selectively degrade components of the extracellular matrix (ECM). 13 They are produced by a variety of cell types, including epithelial cells, fibroblasts, endothelial and inflammatory cells. These proteinases are secreted as inactive zymogens that must be activated in the extracellular compartment. One of the major control points in the regulation of active enzymes is the inhibition of active forms by the family of proteinase inhibitors, called tissue inhibitors of metalloproteinases (TIMPs). As a result of the contributions of MMPs to tumor progression by direct effects on cell proliferation, survival, and angiogenesis, targeting MMP activity has been considered a promising therapeutic approach for anticancer therapy. TIMPs are a family of closely related and secreted proteins that control the MMP activities and also have direct effects on cell growth.
14 Among the four members of the TIMP family, TIMP-2 and TIMP-3 appear to have specific roles in tumor growth and cell invasion. TIMP-2 is able to bind to the C-terminal PEX domain of MMP-2 and MT1-MMP in a ternary complex. 15 The level of TIMP-2 expression is critical since TIMP-2 saturation of MT1-MMP is required to inhibit the process of MT1-MMP activation of pro-MMP-2. It suggests that an imbalance between the proteolytic activity of MMP-2 and TIMP-2 is responsible for the degradation of the ECM. Inactivating MMP-2 could thus control the inhibition of the degradation of ECM, a prerequisite for tumor invasion and metastasis formation. It has also been reported that the C-terminal PEX domain of MMP-2 binds to anb3 integrin receptor, resulting in inhibition of angiogenesis. 16, 17 Binding of TIMP-2 to the PEX domain may compete for binding of MMP-2 to anb3. The role of TIMP-2 in modulating the interaction of MMP-2 with anb3 is, however, unknown. TIMP-3, an MMP inhibitor distinct from TIMP-2, is localized exclusively in the ECM. TIMP-3 also binds to MT1-MMP. TIMP-3 not only inhibits MMPs (MMP-1, -2, -3, -9, -13, and -14), but is also capable of inhibiting the activity of membrane-anchored proteinases containing disintegrins and MMPs (ADAMs) and ADAM with thrombospondin-like domains (ADAMTS): ADAM 10, TACE (TNF-a cleaving enzyme, ADAM 17), ADAMTS4, and ADAMTS5. [18] [19] [20] In addition to inhibition of malignant cell invasion, TIMP-3 promotes apoptotic cell death. [21] [22] [23] The rationale for the design of TIMP-2 and TIMP-3 as therapeutic genes was predicted from our gene profile expression data from two rat HCC, tumorigenic and nontumorigenic, cell lines established from a rat tumor chemically induced by diethylnitrosamine (Tran PL, unpublished results). Both TIMP-2 and TIMP-3 were found underexpressed in the tumorigenic cells, whereas MMP-2 and MMP-9 were both overexpressed. To investigate the potential use of TIMP-2 and TIMP-3 for gene therapy of HCC, we have used two plasmids expressing either the TIMP-2 or TIMP-3 gene under control of the ubiquitous cytomegalovirus (CMV) enhancer/promoter. Gene transfer was performed by means of a novel class of nonviral vectors comprising modified cholesterol, bis-guanidinium-tren-cholesterol (BGTC). 24 We have assessed a protocol using repeated administrations of plasmids into xenografted human HuH7 HCC in athymic mice. We also investigated the bystander effectmediated tumor cell killing of HuH7 tumor cells by TIMP-2 and TIMP-3 proteins. Our results showed that repeated injections of plasmid encoding either the TIMP-2 or TIMP-3 gene could achieve in vivo significant inhibitory effects on angiogenesis, and tumor local growth and invasion.
Methods

Animals
Seven-week-old female athymic nude mice (SWISS) were purchased from Janvier (Orle´ans, France) and acclimated for 15 days. At 24 hours before implantation of HuH7 cells, they were irradiated with a dose of 5 Gy. All animal experiments were reviewed and approved by institutional committees for animal care and use, and for recombinant DNA research (Ministe`re de l'Agriculture, France).
Construction of recombinant plasmids
The plasmid pSK.CMVTIMP-2 was constructed by introducing the cDNA of TIMP-2, kindly provided by Dr Y-A DeClerck (Division of Hematology/Oncology, Children's Hospital of Los Angeles), into the EcoRI sites of pSK.CMV containing the enhancer/promoter CMV sequence and an SV40 polyadenylation sequence. 25 The plasmid pSK.CMVTIMP-3 was constructed by introducing the blunted fragment AgeI-NheI containing the cDNA of TIMP-3 from pBlast.HTLVTIMP-3 (Cayla, Toulouse, France) into the EcoRV sites of pSK.CMVpolyA, as described above. The construction of pSK.CMVnlslacZ was reported in Tran et al. 25 Cell culture and in vitro gene transfer
The human HCC cell lines (HepG2, Hep3B, and HuH7) were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD) containing 10% FCS, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
Transfection experiments were performed with 5 mg of plasmid DNA, pSK.CMVnlslacZ, pSK.CMVTIMP-2, pSK.CMVTIMP-3, or pBlast.HTLVTIMP-3, using a lipoplex formulation containing BGTC and a neutral lipid, di-oleoyl-phosphatidylethanolamine (DOPE) in a lipid/DNA charge ratio of 6, in six-well plates containing 1.8 Â 10 5 cells, as described by Vigneron et al. 26 
Gelatin zymography and immunoblotting
Production of gelatinases, MMP-2 and MMP-9, by HuH7 tumor cells was detected by gelatin zymography as described. 27 Briefly, 24 hours after transfection, cells were washed and incubated in serum-free medium for a further 24 hours. The conditioned media (2 ml) were concentrated in 80% ammonium sulfate as described. 28 The resuspended precipitates were dialyzed and concentrated by filtration (Millipore, Bedford, MA). Gels (8% polyacrylamide/SDS), impregnated with 0.1% gelatin (EIA grade reagent, Biorad Laboratories, Hercules, CA), were run. Removing of SDS was performed by incubating for 2 hours in 2.5% Triton X-100. The gels were then incubated overnight in 50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 10 mM CaCl 2 at 37 1C. Gels were stained with 0.25% Coomassie Brilliant Blue (R250; Sigma, l'Arbesles, France). Bands with gelatinolytic activity were visualized against a dark background.
Concentrated supernatants of (10 ml) of transfected and untransfected HuH7 cell cultures were solubilized in 30 ml of reducing Laemmli buffer for analysis of secreted TIMP proteins. 29 All samples were electrophoresed in 12% polyacrylamide-SDS gels and membranes were probed with either a mouse anti-human TIMP-2 antibody (R&D, Abingdon, UK), or a mouse anti-human TIMP-3 antibody (ICN Biomedicals Inc., Aurora, OH), and a peroxidase-linked swine anti-mouse IgG (Amersham International, UK). Bands were visualized using enhanced chemiluminescence (ECL, Amersham International, UK).
Assessment of bystander effect
HuH7 cells were transfected as described above, and incubated in medium containing 10% SVF for 24 hours. Cells were detached, washed with PBS, suspended in serum-free culture medium, mixed in various ratios (25, 50 , 75 and 100% of transfected cells) with untransfected HuH7 cells, and plated onto 96-well plates. Cultures were incubated for 48, 72, and 96 hours. The number of viable cells was determined at different time points using a nonradioactive cell proliferation MTT assay (CellTiter 96 Aqueous Non-radioactive Cell Proliferation Assay; Promega, Madison,WI).
To obtain conditioned medium, HuH7 cells were transfected as described above and incubated in medium containing 10% SVF for 24 hours, washed with PBS, then incubated for 72 hours in serum-free culture medium. Conditioned medium was added on untransfected HuH7 cells, grown on 96-well plates, mixed with fresh serum-free culture medium in different ratios (30 and 60% of conditioned medium). Viability of cells was determined after 96-hours incubation with MTT assay.
Hepatocellular carcinoma models in nude mice and repeated treatment protocol
Three independent experiments were performed. In a representative experiment, 90 athymic mice were given s.c. injections in the right flank with 5 Â 10 6 HuH7 cells. When tumors reached a mean size of 5 mm in diameter, mice were randomly divided into four treatment groups as follows:
pSK.CMVTIMP-2 (n ¼ 13, group I), pSK.CMVTIMP-3 (n ¼ 13, group II), pSK.CMVTIMP2+pSK.CMVTIMP-3 (n ¼ 13, group III), and pSK.CMVnlslacZ (n ¼ 12, group IV). They were weighed, and the tumor volume was measured with calipers. Nonviral vectors containing 5 mg of each plasmid and cationic lipids were directly injected, in a total volume of 100 ml into the growing tumor from three directions, twice a week, for 5 weeks. Size of the tumor was measured twice weekly with calipers in three dimensions. Mice were killed when the tumor size reached a volume72000 mm 3 , whereas the remaining treated mice were killed for analyses on day 33 or 36. Mean tumor size is represented as the mean7SE mm 3 .
Histological analysis and quantitation
On the day of sacrifice, animals were killed to excise s.c. tumors. Fragments of tumors were snap frozen in liquid nitrogen in O.C.T. (Tissue-Tek, Miles Laboratories, Elkhart, IN), or fixed in 3.7% formaldehyde and processed for hematoxylin and eosin (H&E), Masson trichrome staining, and immunohistochemistry as described previously. 25 Anti-CD34 monoclonal antibody was used at a dilution of 1:50 (clone QBEND10 Coulter Inc., USA). Apoptosis was evaluated using the Apoptag peroxidase kit (Appligene, Illkirch, France).
Immunohistochemistry staining with CD34 monoclonal antibody was quantified by counting the number of positive vessels per microscopy field. A total of 10 randomly chosen microscopy fields was evaluated for each tissue specimen and the mean and standard deviation (SD) were calculated.
Statistical analysis
All data were analyzed using a paired Student's t-test.
Results
In vitro and in vivo gene transfer and expression of TIMP-2 and TIMP-3
We initially assessed MMP activity secreted from various human HCC cells (Hep3B, HepG2, and HuH7). Gelatin zymography revealed that HuH7 cells produced high levels of gelatinolytic MMP-2 and -9 activities (Fig 1a,  lanes 1 and 2) , as reported by Brand et al. 27 No gelatinase activity was detected for Hep3B and HepG2 (not shown), in agreement with Giannelli et al. 28 Upon transfection of HuH7 cells with either pSK.CMVTIMP-2, pSK. CMVTIMP-3, or pBlast.HTLVTIMP-3, a reduction in the gelatinolytic bands was observed (Fig 1a, lanes 3-5) .
The expression of secreted TIMP-2 and TIMP-3 was assessed by Western blot analysis in serum-free medium of HuH7 HCC cells, transfected with plasmid expressing either TIMP-2, or TIMP-3, or BGTC/DOPE as control. Figure 1b displays the detection of TIMP-2 (MWB 21,500) and two forms of TIMP-3, glycosylated (MWB 24,000) and unglycosylated (MWB21,500), in the supernatants of pSK.CMVTIMP-2-, or pSK.CMVTIMP-3-transfected cells but not in BGTC/DOPE-transfected cells.
In vivo transduction with plasmids expressing TIMP-2 or TIMP-3 gene was analyzed in transplanted HuH7 tumors. Images from 5-mm cryosections of tumor fragments immunostained with monoclonal antibodies directed against either TIMP-2, or TIMP-3, and counterstained with hematoxylin, revealed the intracellular distribution of TIMP proteins localized within the cytoplasm (Fig 2a, b, arrowheads) .
In vitro characterization of the biologic effects of secreted TIMP-2 and TIMP-3
The antiproliferative activities and biologic effects of TIMP-2 and TIMP-3 on HuH7 cells were investigated following cell transfection using an optimum formulation of lipoplexes, as reported in Materials and methods. A dose of 5 mg of DNA plasmid expressing either TIMP-2 or TIMP-3 was sufficient to produce an inhibitory effect on HuH7 cell growth 96 hours after transfection, as measured by cell viability using MTT colorimetric assay. This effect is displayed in Figure 3a by cells transfected with either CMVTIMP-2 (100%), or CMVTIMP-3 (100%). In our transfection conditions, we assumed that 80% of the cell population was transduced, as revealed by cell staining with the b-galactosidase substrate X-Gal (not shown). We then demonstrated the cytotoxic bystander effect of secreted TIMP proteins released from transduced cells on adjacent unmodified cells. At 24 hours after transfection, cells were detached and mixed with untransfected HuH7 cells in various ratios, and incubated for a period of 48-96 hours. The number of viable cells were monitored by colorimetric assay. Figure 3a (inset) displays the kinetics of cytotoxic bystander effects when only 50% of transfected cells with either CMVTIMP-2, or CMVTIMP-3 were mixed with 50% of untransfected cells. As reported above, assuming that 40% of the 50% of transfected cells were transduced, it appeared that within 48 hours, the transduced cells were able to kill B80% of cells, in both cases, following transduction with either TIMP-2, or TIMP-3. The number of killed cells increased to 97% in both cases within 96 hours. In addition, in Figure 3a , our results revealed that in culture containing 25% HuH7 cells transfected with CMVTIMP-2, 87% of the cells were killed within 96 hours. The number of killed cells was increased to 96, 98.3 and 99%, respectively, in cultures containing 50, 75 and 100% TIMP-2-transfected cells, respectively. Expression of the Antitumor efficacy of multiple delivery of TIMP-2 and TIMP-3 P-L Tran et al soluble TIMP-3 by transfected cells also displayed a cytotoxic bystander effect in culture containing 25 and 50% HuH7 transfected with CMVTIMP-3. A total of 79 and 97% of the cells were killed, respectively, within 96 hours, whereas all HuH7 cells were dead in cultures containing 75 and 100% TIMP-3-transduced cells (Fig  3a) . The bystander effect, originating from cells transduced by TIMP-2, or TIMP-3, thus describes the biologic responses of surrounding untransfected cells. These physiological processes are time-dependent and increase with cell concentrations. Our observations demonstrated the potent activity and stability of the soluble TIMP proteins in the conditioned medium. We also demonstrated that incubation of untransfected HuH7 cells, for 96 hours, in culture medium containing 30% of conditioned medium from either CMVTIMP-2-or CMVTIMP-3-transfected cells resulted in death of 86-91% of HuH7 cells (Fig 3b) . A total of 91 and 100% of cells died when cells were incubated, for 96 hours, in culture medium containing 60% of conditioned medium from either TIMP-2-, or TIMP-3-transduced cells, respectively. In conclusion, these results showed that both TIMP-2 and TIMP-3 proteins retained potential bystander-mediated killing of tumor cells. Both TIMP-2 and TIMP-3 proteins appeared to display identical effects.
Treatment of established HuH7 tumors by repeated injections of TIMP-2 and TIMP-3
HCC tumors were established in vivo in nude mice through the s.c. injection of HuH7 cells as described in Materials and methods. After 3 weeks to allow the tumors to grow to 80-150 mm 3 in size, they were intratumorally injected with 5 mg of either pSK.CMVTIMP-2, or pSK.CMVTIMP-3, or pSK.CMVTIMP-2+pSK. CMVTIMP-3, or pSK.CMVnlslacZ. The injections were repeated twice a week for 5 weeks. No treatment-related toxicity was observed with the cationic cholesterol-based formulation. Average tumor sizes of each individual treatment group versus control group (lacZ) were plotted (Fig 4a-c) .
Inhibition of tumor growth was manifested in all three groups of mice treated with TIMPs. Comparisons of average tumor sizes of the treated groups, pSK.CMVTIMP-2, pSK.CMVTIMP-3, and combined plasmids, pSK.CMVTIMP-2+pSK.CMVTIMP-3 versus control group, pSK.CMVnlslacZ, showed significant differences in average tumor sizes between the groups, Po.007, Po.004, and Po.004, respectively. On day 26 post-treatment, the mean tumor volume in all TIMPstreated groups of mice was reduced by 70% as compared with the one treated with the plasmid encoding lacZ (Fig 4a-c) . The combined treatment, TIMP-2+TIMP-3, showed no synergic effect when both plasmids expressing TIMP-2 and TIMP-3 were used together. The formation of large aggregates of the lipoplexes with increased DNA concentration could result in low efficacy of gene transfer. This procedure should be better sterically stabilized by the addition of modified poly(ethyleneglycol) (Chol-PEG), as soon as we can have access to this patented compound. 30 Macroscopic analyses of tumors treated with either TIMP-2 or TIMP-3 showed a disintegrated white appearance of the tumors (not shown). However, a hemorrhaged and hypervascularized aspect was noted in all tumors treated with pSK.CMVnlslacZ (not shown). Histological analyses of paraffin-embedded sections were performed to compare the characteristics of tumors, vessel density, hemorrhage formation, apoptotic index, and morphological appearance, from control and treated mice. Staining with trichrome Masson revealed inhibition of tumor growth and a deposition of a thick connective tissue capsule rich in collagen that prevented the local invasion (not shown). This observation is consistent with the one previously reported by DeClerk et al. 31 Tumor vascularization was thus measured on tumor sections immunostained with an anti-CD34 antibody. Figure 5(b,c) shows that angiogenesis inhibitor treatment with TIMP-2, or TIMP-3, drastically decreases blood vessel density, as compared to tumors treated with lacZ (Fig 5a) . A significant reduction of tumor angiogenesis is obtained in tumor overexpressing the combined TIMP-2+TIMP-3 (Fig 5d) . CD-34 staining of blood vessels was then quantified in the tumor sections by counting the number of positive vessels per microscopic field. Ten randomly chosen microscopic fields were counted for each stained section and the mean is reported in Figure 6 . As shown in the figure, a significant difference was observed between blood vessel density from tumor sections treated with TIMP-2 or TIMP-3, and that of control tumor section (Po.0001). It is noted that both plasmids expressing TIMP-2 and TIMP-3 produced an additive effect on the inhibition of angiogenesis, even though no synergistic inhibition of tumor growth was observed with the combined treatment. A possible explanation is that tumor transduction was insufficient due to poor lipoplex formulation.
H&E and TUNEL staining assessed morphology and apoptotic cell labeling. In tumors treated with plasmid expressing either TIMP-2, or TIMP-3 alone and stained by HE, large necrotic areas (arrows) containing numerous apoptotic cells are noted (Fig 7a, c) . Instead, in tumors treated with lacZ, in which spontaneous necrosis could happen, a few apoptoctic cells were apparent (Fig 7g) . TUNEL assay of sections from mice treated with TIMP-2 and TIMP-3 demonstrates a large amount of apoptotic cells containing fragmented nuclei within necrotic areas (Fig 7b, d, and insets) . Whereas in sections from mice treated with lacZ, apoptototic cells are rather located at the periphery of the tumor and the necrosis (Fig 7h) . Figure 7e indicates that treatment with both TIMP-2 and TIMP-3 could achieve a bulky effect on cell apoptosis. TUNEL assay displayed massive acidophilic bodies containing fragmented nuclei (Fig 7f) .
Discussion
HCC is a refractory disease for which current treatment modalities are ineffective. [3] [4] [5] [6] Better therapeutic strategies need to be developed. Several laboratories have investigated the feasibility of using gene therapy approach to the treatment of HCC. Strategies for p53 tumor suppressor gene therapy have been proposed that use retroviral, 32 adenoviral. 12, 33, 34 and lipid-based delivery 35 systems. A second strategy involves suicide HSV-tk gene therapy. 10, 11, 36, 37 Habib et al 38 reported a phase I study based on a replication competent E1-deleted adenovirus to target primary and secondary liver tumor. Most of these strategies were carried out using recombinant adenoviruses because they are efficient mediators of gene transfer. However, the major risk factor in using human-modified adenovectors is a possible recombination with wild-type adenovirus. In addition, the mounted antiviral immune response prevents readministrations of the vectors. We report herein a novel strategy that associates secreted proteins retaining both bystander and proapoptotic properties with the use of a nonviral system delivery. The tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3 were produced by a novel class of vectors, comprising BGTC/DOPE lipoplexes that are nontoxic and nonimmunogenic, and thus may allow repeated administrations. 24, 26 The tumor microenvironment contributes substantially to the establishment of tumors and their growth. 39, 40 MMPs are essential in promoting tumor progression because they are produced and secreted by tumor cells to degrade basement membrane and ECM components, and thereby facilitate tumor cell invasion. 41 Our experiments were designed to address whether treatment with selective inhibitors of MMPs could slow or arrest tumor growth. In these intervening studies, mice bearing growing HCC HuH7 tumors were treated with 5 mg of DNA plasmid expressing either TIMP-2, or TIMP-3, or combined treatment with TIMP-2 and TIMP-3, twice a week for 5 weeks. We showed that this dose regimen using a low DNA concentration was sufficient to slow HuH7 tumor growth in tumors treated with either TIMP-3, or combined TIMP-2 and TIMP-3, and arrest tumor growth in those treated with TIMP-2 (Fig 4a-c) . These results corroborate the inhibitory effect of TIMP-2 on tumor growth of LLC, C51, and MDA-MB-231 tumor cells transplanted into nude mice, using adenoviral vectors. 42 In addition, our data show, for the first time, an in vivo inhibitory effect of TIMP-3 on HCC tumor growth. TIMP-3 overexpression was reported to induce, in vitro, apoptotic cell death of HeLa, HT1080, MCF-7, and melanoma cells. 20, 21 Ahonen et al 43 recently reported an in vivo effect of a recombinant RAdTIMP-3 on melanoma cells and squamous cell carcinoma xenografted into SCID mice. 43 Our results on histologic examination of tumor sections revealed large necrotic areas containing numerous apoptotic cells in tumors treated with either TIMP-2, or TIMP-3 (Fig 7a-d) , whereas the combined treatment, TIMP-2 and TIMP-3, displayed high efficacy with a bulky effect on cell apoptosis (Fig 7e, f) . Both TIMP-2-and TIMP-3 could also prevent expansion and invasion of Antitumor efficacy of multiple delivery of TIMP-2 and TIMP-3 P-L Tran et al tumor growth by reducing and inhibiting angiogenesis during tumor progression (Fig 5b-d) . We showed in cell cultures that (1) expression of TIMP-2 and TIMP-3 by transfected HuH7 cells could produce bystander-mediated tumor cells killing of untransfected HuH7 cells, (2) the soluble forms of TIMP-2 and TIMP-3 released by transfected cells exerted a cytotoxic effect on untransfected HuH7 cells (Fig 3a,b) . Taken together, our results suggest that TIMP-2-and TIMP-3-mediated inhibition of angiogenesis, induction of apoptosis, and inhibition of local invasion might contribute to the bystander effect on TIMP-2 and TIMP-3-mediated tumor suppression.
In our present experiments, we have adopted a strategy using repeated injections of a nonviral formulation of low DNA concentration, which proved successful in showing an efficient antitumor response of TIMP-2 and TIMP-3. In previous experiments using repeated intratumor administrations of an adenoviral vector, Ad5.CMVp53, at a high dose of 5 Â 10 11 PFU per injection, we failed to demonstrate any antitumor response in the mutated p53 HuH7 HCC cells transplanted into nude mice (PL Tran, unpublished results). Such a lack of efficacy of recombinant Adp53 to inhibit tumor growth was also reported by Ahonen et al, 43 in melanoma cells and squamous-cell carcinoma xenografted into SCID mice. It showed that in vivo inhibition of tumor growth by overexpression of p53 might not correlate with the expected in vitro biological effects. Instead, strategies using TIMP-2 and TIMP-3 may have particular advantages over cell death strategies as the proteins are secreted. These secreted proteins, TIMP-2 and TIMP-3, induce a bystander effect such that death of untransfected cells can occur. Additionally, TIMPs-induced cell death does not require systemic delivery of a prodrug, which is necessary for the HSVtk/ganciclovir cell death strategy. Secreted proteins associated with efficient nonviral system for gene delivery would provide potential means to prevent dissemination of liver cancer cells. Indeed, HCC is an aggressive but slow-growing tumor. Long-term survival for patients with HCC results from surgical resection or liver transplantation. However, tumor recurrence as well as metastasis formation in most patients (80%) is common after surgery. Giannelli et al 44 suggested that an imbalance between MMP-2 and TIMP-2 in HCC primary nodule tissues could play a role in the spread of HCC cells. Targeted strategies using TIMP-2 and TIMP-3 may reduce or even prevent the metastatic ability of HCC cells by modulating their proteolytic activity, thus improving the outcome of patients. In this respect, we have set up multiple delivery of therapeutic vectors to rat HCC chemically induced by DEN, in a noninvasive manner, by the intra-arterial hepatic route of administration. This procedure increased vector concentrations in tumors and reduced systemic exposure. Nevertheless, such protocol using repeated administrations of recombinant adenoviruses was not useful since the expression of transgene was hindered by the development of antiviral immune response. 11 The present gene delivery system, BGTC/DOPE, has the advantage of being nonimmunogenic and can be given repeatedly. 24 In addition, these vectors conjuguated to poly(ethyleneglycol) could be sterically stabilized for in vivo use. 30 Further studies are needed to explore these alternative gene therapy strategies for HCC.
